Last Defendants Settle With Sanofi Over Eloxatin

Law360, New York (April 6, 2010, 7:08 PM EDT) -- Sanofi-Aventis SA on Tuesday announced settlements with Hospira Inc., Par Pharmaceuticals Inc. and Actavis, the three remaining defendants in patent litigation over cancer drug Eloxatin.

The three companies agreed to resolve the litigation on the same terms as earlier settling defendants and to keep generic versions of Eloxatin off store shelves for about two years, Sanofi said.

The deals end lawsuits in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Columbia, the plaintiff said....
To view the full article, register now.